JP2016504400A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504400A5
JP2016504400A5 JP2015552060A JP2015552060A JP2016504400A5 JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5 JP 2015552060 A JP2015552060 A JP 2015552060A JP 2015552060 A JP2015552060 A JP 2015552060A JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
aryl
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504400A (ja
JP6276289B2 (ja
Filing date
Publication date
Priority claimed from GBGB1300435.3A external-priority patent/GB201300435D0/en
Application filed filed Critical
Publication of JP2016504400A publication Critical patent/JP2016504400A/ja
Publication of JP2016504400A5 publication Critical patent/JP2016504400A5/ja
Application granted granted Critical
Publication of JP6276289B2 publication Critical patent/JP6276289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552060A 2013-01-10 2014-01-10 ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用 Active JP6276289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300435.3A GB201300435D0 (en) 2013-01-10 2013-01-10 Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
GB1300435.3 2013-01-10
PCT/EP2014/050422 WO2014108520A1 (en) 2013-01-10 2014-01-10 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

Publications (3)

Publication Number Publication Date
JP2016504400A JP2016504400A (ja) 2016-02-12
JP2016504400A5 true JP2016504400A5 (enExample) 2017-01-05
JP6276289B2 JP6276289B2 (ja) 2018-02-07

Family

ID=47757796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552060A Active JP6276289B2 (ja) 2013-01-10 2014-01-10 ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用

Country Status (21)

Country Link
US (4) US9682943B2 (enExample)
EP (2) EP3115357B1 (enExample)
JP (1) JP6276289B2 (enExample)
KR (1) KR102166665B1 (enExample)
CN (1) CN105189452B (enExample)
AU (2) AU2014204831C1 (enExample)
CA (1) CA2896976C (enExample)
DK (1) DK2943467T3 (enExample)
ES (2) ES2831453T3 (enExample)
GB (1) GB201300435D0 (enExample)
HR (1) HRP20161208T1 (enExample)
HU (1) HUE030848T2 (enExample)
IL (1) IL239629B (enExample)
LT (1) LT2943467T (enExample)
MX (1) MX370491B (enExample)
PL (1) PL2943467T3 (enExample)
PT (1) PT2943467T (enExample)
RS (1) RS55185B1 (enExample)
RU (1) RU2654910C2 (enExample)
SI (1) SI2943467T1 (enExample)
WO (1) WO2014108520A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
JP6994939B2 (ja) * 2014-07-02 2022-02-04 インフレクティス・バイオサイエンス プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用
EP3280405B1 (en) 2015-04-08 2021-07-07 United Kingdom Research and Innovation Inhibitors and their uses
US9501793B1 (en) * 2015-06-04 2016-11-22 Herofi, Inc. Archetecture and associated methodology for data standardization and utilization in retail industry applications
CA2992674A1 (en) * 2015-07-31 2017-02-09 Inflectis Bioscience Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
US11166464B2 (en) * 2017-03-06 2021-11-09 The United States Of America, As Represented By The Secretary Of Agriculture Self-assembled active agents
WO2019215470A1 (en) 2018-05-09 2019-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies
CN113072467B (zh) * 2021-03-24 2022-04-12 南方医科大学 含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用
WO2024105168A1 (en) 2022-11-18 2024-05-23 Inflectis Bioscience Novel combinations useful for the treatments of als
US20240293343A1 (en) 2023-02-13 2024-09-05 Inflectis Bioscience Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications
KR20250157531A (ko) * 2023-03-16 2025-11-04 교토후고리츠다이가쿠호진 Ampk 활성화 및/또는 chop 억제에 의한 치료가 가능한 질환 및 장애의 치료를 위한 sephin1 및 관련 화합물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223492A (en) 1967-10-13 1971-02-24 American Home Prod Guanidines
US3541218A (en) * 1969-06-18 1970-11-17 Lilly Co Eli Omicron-fluorobenzylaminoguanidine for diabetes
SE7607653L (sv) 1976-07-05 1978-01-06 Haessle Ab Substituerade triazoler
EP0600973A1 (en) * 1991-08-27 1994-06-15 The Upjohn Company A method for treatment of metabolic disorders and metabolism
DE793646T1 (de) * 1994-11-23 1999-12-30 Pharmacia & Upjohn Co., Kalamazoo Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
AU7802700A (en) 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
FR2812812B1 (fr) 2000-08-08 2002-10-11 Philippe Gorny Medicament destine notamment a combattre les dysfonctions sexuelles
KR20060088885A (ko) * 2003-09-25 2006-08-07 아카디아 파마슈티칼스 인코포레이티드 뉴로펩티드 ff 리셉터 2의 작용제를 이용한 신경병증성통증 치료 방법
CN1875271A (zh) * 2003-09-25 2006-12-06 阿卡蒂亚药品公司 用神经肽ff受体2激动剂治疗神经痛
EP1908464A1 (en) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases
EP1908465B1 (en) * 2006-10-04 2009-04-29 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating prion-based diseases
WO2008091681A2 (en) 2007-01-23 2008-07-31 Housey Gerard M Theramutein modulators
US20120202814A1 (en) 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
ES2587232T3 (es) 2010-07-20 2016-10-21 Vestaron Corporation Triazinas y pirimidinas insecticidas
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases

Similar Documents

Publication Publication Date Title
RU2015127827A (ru) Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков
JP2017509586A5 (enExample)
AR122902A2 (es) Compuestos terapéuticamente activos y sus métodos de preparación
JP2017071634A5 (enExample)
JP2016506960A5 (enExample)
JP2015520769A5 (enExample)
JP2016515561A5 (enExample)
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
JP2016505637A5 (enExample)
JP2014521688A5 (enExample)
JP2013537203A5 (enExample)
JP2016503797A5 (enExample)
PE20141282A1 (es) Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
JP2016506961A5 (enExample)
JP2017533968A5 (enExample)
JP2013533879A5 (enExample)
JP2014511891A5 (enExample)
JP2014511892A5 (enExample)
JP2016506962A5 (enExample)
JP2016505614A5 (enExample)
JP2017504635A5 (enExample)
JP2016507575A5 (enExample)
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
JP2016531126A5 (enExample)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий